Skip to content
HowShorted

Flexion Therapeutics Inc short interest in 2018

In 2018, Flexion Therapeutics Inc's disclosed short interest ran from 26.52% of shares outstanding on 12 Jan 2018 to 24.52% on 31 Dec 2018, a change of -2.00 percentage points. The year's high was 31.10% on 28 Sep 2018 and its low 24.52% on 31 Dec 2018, averaging 28.18% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 30.00 days on 13 Jul 2018. Full history: Flexion Therapeutics Inc.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021

Aggregate net short position time series for Flexion Therapeutics Inc in 2018

2018 in figures

Start of year
26.52% (12 Jan 2018)
End of year
24.52% (31 Dec 2018)
Change
-2.00 pp
High
31.10% (28 Sep 2018)
Low
24.52% (31 Dec 2018)
Average
28.18%
Highest days to cover
30.00 (13 Jul 2018)
SEC filings marked
8

Every report in 2018

Flexion Therapeutics Inc short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201826.52%15.84
31 Jan 201826.26%12.44
15 Feb 201827.65%15.28
28 Feb 201827.70%13.31
15 Mar 201828.16%13.2910-K filed, results (8-K)
29 Mar 201828.72%12.38
13 Apr 201829.16%13.64
30 Apr 201829.65%21.35
15 May 201829.44%18.7010-Q filed, results (8-K)
31 May 201829.84%22.78
15 Jun 201829.99%27.50
29 Jun 201828.90%23.14
13 Jul 201829.03%30.00
31 Jul 201827.96%27.14
15 Aug 201828.07%16.7410-Q filed, results (8-K)
31 Aug 201829.31%22.41
14 Sep 201829.91%27.77
28 Sep 201831.10%16.21
15 Oct 201829.77%19.96
31 Oct 201826.53%11.30
15 Nov 201826.83%11.1810-Q filed, results (8-K)
30 Nov 201826.40%19.98
14 Dec 201824.94%13.74
31 Dec 201824.52%12.30

See also: Flexion Therapeutics Inc's full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.